Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Luigi, Xerri"'
Autor:
William J. Weiss, Christopher J. Burns, Randy W. Jackson, Greg Moeck, Eugen F. Mesaros, Jodie Hamrick, Susan M Cusick, Boyd Steven A, Bin Liu, Denis M. Daigle, Cassandra L Chatwin, Lisa McLaughlin, Kaitlyn John, Daniel C. Pevear, Allison L. Zulli, Robert E. Lee Trout, Luigi Xerri, Mark Pulse
Publikováno v:
Journal of Medicinal Chemistry
A major antimicrobial resistance mechanism in Gram-negative bacteria is the production of β-lactamase enzymes. The increasing emergence of β-lactamase-producing multi-drug-resistant “superbugs” has resulted in increases in costly hospital Emerg
Autor:
Bin Liu, M. Benvenuti, Christopher J. Burns, G.-H. Chu, Mcgarry Daniel G, Luigi Xerri, Denis M. Daigle, Robert E. Lee Trout, Cecilia Pozzi, Daniel C. Pevear, Stefano Mangani, William J. Weiss, Randy W. Jackson, F. De Luca, Jean Denis Docquier, Susan M Cusick, Jodie Hamrick
Publikováno v:
'Journal of Medicinal Chemistry ', vol: 63, pages: 2789-2801 (2020)
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry
A major resistance mechanism in Gram-negative bacteria is the production of β-lactamase enzymes. Originally recognized for their ability to hydrolyze penicillins, emergent β-lactamases can now confer resistance to other β-lactam drugs, including b
Autor:
Denis M. Daigle, Christopher J. Burns, William J. Weiss, Daniel C. Pevear, Cullen L. Myers, Kaitlyn John, Jodie Hamrick, Robert E. Lee Trout, Susan M Cusick, Mark Pulse, Luigi Xerri, Cassandra L Chatwin, Tsuyoshi Uehara, Gregory Moeck
Publikováno v:
Antimicrobial Agents and Chemotherapy. 65
There is an urgent need for oral agents to combat resistant Gram-negative pathogens. Here, we describe the characterization of VNRX-5236, a broad-spectrum boronic acid β-lactamase inhibitor (BLI), and its orally bioavailable etzadroxil prodrug, VNRX
Autor:
Cassandra L, Chatwin, Jodie C, Hamrick, Robert E L, Trout, Cullen L, Myers, Susan M, Cusick, William J, Weiss, Mark E, Pulse, Luigi, Xerri, Christopher J, Burns, Gregory, Moeck, Denis M, Daigle, Kaitlyn, John, Tsuyoshi, Uehara, Daniel C, Pevear
Publikováno v:
Antimicrobial Agents and Chemotherapy
There is an urgent need for oral agents to combat resistant Gram-negative pathogens. Here, we describe the characterization of VNRX-5236, a broad-spectrum boronic acid β-lactamase inhibitor (BLI), and its orally bioavailable etzadroxil prodrug, VNRX
Autor:
Kaitlyn John, Jodie Hamrick, David A. Six, Denis M. Daigle, Tsuyoshi Uehara, Luigi Xerri, Susan M Cusick, Daniel C. Pevear, Manuela Benvenuti, Cassandra L Chatwin, Christopher J. Burns, Salvador Vernacchio, Randy W. Jackson, Greg Moeck, Bin Liu, Robert E. Lee Trout, Filomena De Luca, Jean Denis Docquier, Stefano Mangani, Cullen L. Myers, Cecilia Pozzi
As shifts in the epidemiology of β-lactamase-mediated resistance continue, carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are the most urgent threats. Although approved β-lactam (BL)-β-lactamase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ebef2baf47b65ca9a3ff1093605020a
http://hdl.handle.net/11365/1095652
http://hdl.handle.net/11365/1095652
Autor:
Jodie C, Hamrick, Jean-Denis, Docquier, Tsuyoshi, Uehara, Cullen L, Myers, David A, Six, Cassandra L, Chatwin, Kaitlyn J, John, Salvador F, Vernacchio, Susan M, Cusick, Robert E L, Trout, Cecilia, Pozzi, Filomena, De Luca, Manuela, Benvenuti, Stefano, Mangani, Bin, Liu, Randy W, Jackson, Greg, Moeck, Luigi, Xerri, Christopher J, Burns, Daniel C, Pevear, Denis M, Daigle
Publikováno v:
Antimicrobial Agents and Chemotherapy
As shifts in the epidemiology of β-lactamase-mediated resistance continue, carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are the most urgent threats.
As shifts in the epidemiology of β-lacta
As shifts in the epidemiology of β-lacta
Autor:
Lisa McLaughlin, Salvador Vernacchio, Daniel C. Pevear, Greg Moeck, Lindsay M. Avery, Luigi Xerri
Publikováno v:
Open Forum Infectious Diseases
Background FEP-TAN (FTB) efficacy and safety are currently being evaluated in a Phase 3 trial (NCT03840148). TAN, a boronic acid-based β-lactamase inhibitor, restores susceptibility to FEP when resistance is driven by SBL or MBL (ie, NDM, VIM). This
Autor:
Luigi Xerri, Antonio Oliver, Cassandra L Chatwin, Cornelius J. Clancy, Barry N. Kreiswirth, Daniel Pevear, Minh-Hong Nguyen, Denis M. Daigle, Natalia Kurepina, Jodie Hamrick, Ryan K. Shields
Publikováno v:
Open Forum Infectious Diseases
Background VNRX-5133 is a cyclic boronate β-lactamase inhibitor (BLI) currently in clinical development with cefepime to treat multidrug-resistant (MDR) infections caused by ESBL- and carbapenemase-producing Enterobacteriaceae (ENT) and P. aeruginos
Publikováno v:
Open Forum Infectious Diseases
Background VNRX-5133 is a cyclic boronate β-lactamase inhibitor (BLI) in clinical development with cefepime for treatment of infections caused by ESBL- and carbapenemase producing Enterobacteriaceae and P. aeruginosa. It is a new generation broad-sp
Autor:
Ian A. Critchley, Alisa W Serio, Kevin M. Krause, Sandra P. McCurdy, Joseph P. Iaconis, Nicole E. Scangarella-Oman, Sachin Bhagwat, Laurent Chesnel, Patricia A. Bradford, Trudy Grossman, Jeff Alder, George A. Williams, Gregory G. Stone, Mary Motyl, Nicole M. Mahoney, Linda A. Miller, Jane E. Ambler, Roger Echols, Luigi Xerri, David Van Veenhuyzen, Judith N. Steenbergen
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 63(11)